Cancel anytime
Generation Bio Co (GBIO)GBIO
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: GBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -67.13% | Upturn Advisory Performance 2 | Avg. Invested days: 21 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -67.13% | Avg. Invested days: 21 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 92.84M USD |
Price to earnings Ratio - | 1Y Target Price 7.5 |
Dividends yield (FY) - | Basic EPS (TTM) -2.19 |
Volume (30-day avg) 135987 | Beta 2.82 |
52 Weeks Range 1.10 - 4.65 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 92.84M USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Dividends yield (FY) - | Basic EPS (TTM) -2.19 | Volume (30-day avg) 135987 | Beta 2.82 |
52 Weeks Range 1.10 - 4.65 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-07 | When AfterMarket |
Estimate -0.28 | Actual -0.23 |
Report Date 2024-11-07 | When AfterMarket | Estimate -0.28 | Actual -0.23 |
Profitability
Profit Margin - | Operating Margin (TTM) -221.27% |
Management Effectiveness
Return on Assets (TTM) -19.29% | Return on Equity (TTM) -86.5% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 1851022 | Price to Sales(TTM) 5 |
Enterprise Value to Revenue 0.1 | Enterprise Value to EBITDA -0.34 |
Shares Outstanding 66792800 | Shares Floating 48816870 |
Percent Insiders 14.51 | Percent Institutions 83.88 |
Trailing PE - | Forward PE - | Enterprise Value 1851022 | Price to Sales(TTM) 5 |
Enterprise Value to Revenue 0.1 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 66792800 | Shares Floating 48816870 |
Percent Insiders 14.51 | Percent Institutions 83.88 |
Analyst Ratings
Rating 4 | Target Price 11.8 | Buy 1 |
Strong Buy 3 | Hold 3 | Sell - |
Strong Sell - |
Rating 4 | Target Price 11.8 | Buy 1 | Strong Buy 3 |
Hold 3 | Sell - | Strong Sell - |
AI Summarization
Generation Bio Co.: A Comprehensive Overview
Company Profile:
History and Background:
Founded in 2018 by Joseph Truitt, Generation Bio is a clinical-stage biotechnology company focused on gene therapy for rare and debilitating diseases. Their proprietary platform, the X-linked gene therapy platform, aims to deliver a single-course treatment for a broad range of severe genetic diseases.
Core Business Areas:
- Gene Therapy Development: Generation Bio focuses on developing adeno-associated virus (AAV)-based gene therapies for rare and devastating diseases.
- X-linked Gene Therapy Platform: This versatile platform allows for the development of gene therapies targeting various tissues and organs.
- Pipeline Development: Generation Bio has a diverse pipeline of gene therapy candidates across various stages of clinical development.
Leadership Team and Corporate Structure:
Leadership:
- Daniel J. Tillett, Ph.D. - President and Chief Executive Officer
- Michael Dyne, Ph.D. - Chief Business Officer
- John D. Butler, M.D. - Chief Medical Officer
- Melanie F. Connor - Chief Financial Officer
- David A. Kirn, M.D., Ph.D. - Chief Scientific Officer
Corporate Structure:
Generation Bio operates as a typical biotechnology company, with a board of directors, executive team, and various departments responsible for research and development, clinical trials, finance, and operations.
Top Products and Market Share:
Top Products and Offerings:
- GEN-301: A gene therapy candidate for the treatment of sickle cell disease.
- GEN-302: A gene therapy candidate for the treatment of transfusion-dependent beta-thalassemia.
- GEN-303/04: A gene therapy candidate for the treatment of methylmalonic acidemia.
- GEN-305: A gene therapy candidate for the treatment of Hunter Syndrome.
Market Share:
Generation Bio's products are still in the development stage and have not yet received regulatory approval. Therefore, they do not currently hold any market share. However, the market size for the diseases they target is significant, offering potential for future growth.
Product Performance and Market Reception:
- GEN-301: Demonstrated positive early clinical results in Phase 1/2 trials.
- GEN-302: Shows promise in preclinical studies, with clinical trials expected to begin soon.
- GEN-303/04: Early preclinical data suggests potential for efficacy.
- GEN-305: Preclinical development is ongoing.
Total Addressable Market:
The total addressable market for Generation Bio's gene therapy candidates is estimated to be in the billions of dollars. This includes the market for:
- Sickle cell disease: Estimated global market size of $4.5 billion by 2027.
- Beta-thalassemia: Estimated global market size of $2.5 billion by 2027.
- Methylmalonic acidemia: Estimated global market size of $250 million by 2027.
- Hunter Syndrome: Estimated global market size of $1 billion by 2027.
Financial Performance:
Recent Performance:
As a pre-revenue company, Generation Bio's financials are focused on research and development expenses. Revenue is expected once their products reach commercialization.
- 2022 Revenue: $0
- 2022 Net Income: $(159.2 million)
- 2022 Cash and Cash Equivalents: $347.2 million
Year-over-Year Comparison:
- Revenue: N/A (pre-revenue)
- Net Income: Loss increasing year-over-year due to ongoing R&D investments.
- Cash and Cash Equivalents: Increasing due to funding rounds and partnerships.
Cash Flow and Balance Sheet:
- Cash flow is primarily driven by R&D expenses and funding activities.
- The balance sheet reflects a strong cash position to support ongoing development activities.
Dividends and Shareholder Returns:
Dividend History:
Generation Bio does not currently pay dividends as it is a pre-revenue company focused on reinvesting its resources into research and development.
Shareholder Returns:
Shareholder returns have been volatile due to the company's early stage and lack of revenue. However, long-term investors are betting on the potential success of their gene therapy pipeline.
Growth Trajectory:
Historical Growth:
Generation Bio has experienced rapid growth in its early years, fueled by funding rounds and pipeline development.
Future Projections:
Future growth will depend on the successful development and commercialization of their gene therapy candidates. The company has ambitious plans to expand its pipeline and reach a global market.
Recent Developments:
- Positive clinical data for GEN-301 in sickle cell disease.
- Initiation of clinical trials for GEN-302 and other pipeline candidates.
- Strategic partnerships with leading pharmaceutical companies.
Market Dynamics:
Industry Overview:
The gene therapy market is experiencing rapid growth and innovation, with numerous companies developing therapies for various diseases.
Market Position:
Generation Bio is well-positioned within the gene therapy market due to its innovative platform and promising pipeline.
Adaptability to Market Changes:
The company's flexible platform allows it to adapt to changing market needs and target new diseases.
Competitors:
Key Competitors:
- Bluebird Bio (BLUE)
- Orchard Therapeutics (ORCH)
- Freeline Therapeutics (FRLN)
- Sangamo Therapeutics (SGMO)
Market Share and Comparison:
Generation Bio is a relatively new company and does not currently have a significant market share. However, it competes with established players in the gene therapy market.
Competitive Advantages and Disadvantages:
Advantages:
- Innovative X-linked gene therapy platform
- Diversified pipeline of gene therapy candidates
- Strong partnerships with leading pharmaceutical companies
Disadvantages:
- Early stage of development
- Limited clinical data
- Lack of revenue
Potential Challenges and Opportunities:
Key Challenges:
- Demonstrating the safety and efficacy of gene therapy candidates in clinical trials.
- Achieving regulatory approval for their products.
- Manufacturing gene therapies at scale and ensuring cost-effectiveness.
- Facing competition from established players in the gene therapy market.
Potential Opportunities:
- Expanding the X-linked gene therapy platform to new diseases.
- Developing novel gene therapy vectors and delivery systems.
- In-licensing promising gene therapy candidates from other companies.
- Partnering with pharmaceutical companies for global commercialization.
Recent Acquisitions (last 3 years):
Generation Bio has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Rating: 7.5/10
Justification:
Generation Bio has a strong foundation for future growth, with an innovative platform, promising pipeline, and experienced leadership team. However, the company is still in the early stages of development and faces significant challenges. The AI-based rating reflects the company's potential but also acknowledges the uncertainties associated with its future success.
Sources and Disclaimers:
This overview is based on information gathered from the following sources:
- Generation Bio website
- SEC filings
- Market research reports
- Industry news articles
This information is intended for educational purposes only and should not be considered as investment advice. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Generation Bio Co
Exchange | NASDAQ | Headquaters | Cambridge, MA, United States |
IPO Launch date | 2020-06-12 | President, CEO & Director | Dr. Cameron Geoffrey McDonough M.D. |
Sector | Healthcare | Website | https://generationbio.com |
Industry | Biotechnology | Full time employees | 174 |
Headquaters | Cambridge, MA, United States | ||
President, CEO & Director | Dr. Cameron Geoffrey McDonough M.D. | ||
Website | https://generationbio.com | ||
Website | https://generationbio.com | ||
Full time employees | 174 |
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.